FY2026 EPS Estimates for Astrazeneca Boosted by Analyst

Astrazeneca Plc (NYSE:AZN) – Equities researchers at Erste Group Bank upped their FY2026 EPS estimates for Astrazeneca in a research note issued to investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now forecasts that the company will earn $10.52 per share for the year, up from their prior estimate of $10.30. The consensus estimate for Astrazeneca’s current full-year earnings is $9.39 per share.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion.

Several other equities research analysts have also issued reports on the company. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Weiss Ratings downgraded Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Performance

Shares of AZN stock opened at $189.66 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The stock’s 50-day moving average is $184.15 and its two-hundred day moving average is $187.47. The firm has a market cap of $294.14 billion, a P/E ratio of 28.48, a PEG ratio of 1.66 and a beta of 0.25.

Hedge Funds Weigh In On Astrazeneca

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mascoma Wealth Management LLC bought a new position in shares of Astrazeneca in the first quarter valued at approximately $26,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca during the 4th quarter worth $26,000. Reflection Asset Management acquired a new position in Astrazeneca in the 4th quarter valued at $31,000. Resources Management Corp CT ADV acquired a new position in Astrazeneca in the 1st quarter valued at $35,000. Finally, Raleigh Capital Management Inc. bought a new position in Astrazeneca in the 1st quarter worth $38,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.